Comera Life Sciences Holdings, Inc. (CMRA): Price and Financial Metrics
CMRA Price/Volume Stats
| Current price | $0.04 | 52-week high | $0.87 |
| Prev. close | $0.06 | 52-week low | $0.03 |
| Day low | $0.04 | Volume | 2,000 |
| Day high | $0.05 | Avg. volume | 21,414 |
| 50-day MA | $0.04 | Dividend yield | N/A |
| 200-day MA | $0.25 | Market Cap | 1.26M |
CMRA Stock Price Chart Interactive Chart >
Comera Life Sciences Holdings, Inc. (CMRA) Company Bio
Comera Life Sciences Holdings, Inc. operates as a pre-clinical biotechnology company. It develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. The company's SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. Its products pipeline include CLS-001, an SQ formulation of a marketed, IV administered monoclonal antibody therapeutic for Crohn's disease and ulcerative colitis; CLS-002, an SQ formulation of a marketed, IV-administered immuno-oncology targeted monoclonal antibody for various oncology indications. The company was founded in 2014 and is based in Woburn, Massachusetts.
Latest CMRA News From Around the Web
Below are the latest news stories about COMERA LIFE SCIENCES HOLDINGS INC that investors may wish to consider to help them evaluate CMRA as an investment opportunity.
Comera Life Sciences Designates Dorothy Clarke to Board of DirectorsBy Karen E. Roman Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a company which develops biologic medicines, announced it has appointed Dorothy Clarke to its board of directors. Ms. Clarke previously held leadership roles at Johnson & Johnson for over two decades and specialized in law, regulatory affairs, compliance, and data protection, the company […] |
Comera Life Sciences Appoints Dorothy Clarke to Board of DirectorsDorothy Clarke Dorothy Clarke WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. “Dorothy’s extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way |
Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights– Final stage of technical evaluation near completion in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera’s global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technology – – Completed previously announced $4.1 million private placement of shares of Comera’s common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – WOBURN, Mass., N |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic worth checking out on Wednesday and we have all the latest news happening this morning! |
CMRA Price Returns
| 1-mo | -9.09% |
| 3-mo | -43.66% |
| 6-mo | -87.32% |
| 1-year | -95.01% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -27.27% |
| 2023 | -95.53% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...